Literature DB >> 9734368

Prospects for live attenuated HIV.

R C Desrosiers.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 9734368     DOI： 10.1038/1949

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  11 in total

1.  Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.

Authors:  Barbara L Shacklett; Karen E S Shaw; Lou A Adamson; David T Wilkens; Catherine A Cox; David C Montefiori; Murray B Gardner; Pierre Sonigo; Paul A Luciw
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Evolutionary dynamics of escape from biomedical intervention.

Authors:  Yoh Iwasa; Franziska Michor; Martin A Nowak
Journal:  Proc Biol Sci       Date:  2003-12-22       Impact factor: 5.349

3.  Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.

Authors:  S M Blower; K Koelle; D E Kirschner; J Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

4.  Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines.

Authors:  Jodi K Craigo; Shannon Durkin; Timothy J Sturgeon; Tara Tagmyer; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Vaccine       Date:  2006-09-22       Impact factor: 3.641

5.  Improving the safety of a conditional-live human immunodeficiency virus type 1 vaccine by controlling both gene expression and cell entry.

Authors:  Atze T Das; Chris E Baldwin; Monique Vink; Ben Berkhout
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail.

Authors:  P N Fultz; P J Vance; M J Endres; B Tao; J D Dvorin; I C Davis; J D Lifson; D C Montefiori; M Marsh; M H Malim; J A Hoxie
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1.

Authors:  W B Dyer; G S Ogg; M A Demoitie; X Jin; A F Geczy; S L Rowland-Jones; A J McMichael; D F Nixon; J S Sullivan
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

8.  Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.

Authors:  P J Klasse
Journal:  Adv Biol       Date:  2014-09-09

9.  HIV vaccine: it may take two to tango, but no party time yet.

Authors:  Ben Berkhout; William A Paxton
Journal:  Retrovirology       Date:  2009-10-09       Impact factor: 4.602

Review 10.  Tet-On Systems For Doxycycline-inducible Gene Expression.

Authors:  Atze T Das; Liliane Tenenbaum; Ben Berkhout
Journal:  Curr Gene Ther       Date:  2016       Impact factor: 4.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.